Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome

Artículo original

Año: 2023

Hernandez-Jerez, AF; Adriaanse, P; Aldrich, A; Berny, P; Coja, T; Duquesne, S; Focks, A; Millet, M; Pelkonen, O; Pieper, S; Tiktak, A; Topping, CJ; Widenfalk, A; Wilks, M; Wolterink, G; Angeli, K; Recordati, C; Van Durseen, M; Aiassa, E; Lanzoni, A; Losti

Título: EFSA JOURNAL

• Q2